Blog
gb English GB
  • frFrançais
  • gbEnglish GB
  • nlNederlands
Horus Pharma Belux
  • logo
  • About
    • Corporate Social Responsibility
    • Expertise
    • History
    • Values and commitment
    • Team
    • Key Figures
  • Products
    Ophthalmology Ophthalmology
    • Corneal edema
    • Ocular dryness
    • Glaucoma
    • DME
    • Allergic conjunctivitis
    Eye Micronutrition Eye Micronutrition
    • Food supplements
    Dermatology Dermatology
    • Eyelids Care and Hygiene
    Chirurgie Chirurgie
  • INTERNATIONAL
    • Export a strategic pillar
    • Horus Pharma around the world and our subsidiaries
  • R&D
    • Research Domains
    • Agreements and licenses / patents
  • CAREERS
    • Horus spirit & our trades
    • Recruitment
  • NETWORK OF EXPERTS
  • News
  • Webinars
    • Difficult cases in cornea
    • Satellite symposium – OB 2021
  • CONTACT
Menu
  • Home
  • About
  • +
    Products
    • +
      Ophthalmology
      • Corneal edema
      • Ocular dryness
      • Glaucoma
      • DME
      • Allergic conjunctivitis
    • +
      Eye Micronutrition
      • Food supplements
    • +
      Dermatology
      • Eyelids Care and Hygiene
    • Chirurgie
  • R&D
  • INTERNATIONAL
  • Careers
  • News and Diaries
  • Webinars
  • documents Iluvien
  • Contact us
> About> Key Figures

KEY FIGURES

HORUS PHARMA

The performance of Horus Pharma is based on a reasoned dynamic of Research and Development, recruitment and international conquest.

Recording two-digit growth since its inception, Horus Pharma ended the year 2019 with a turnover of 64 million€. A good progress which is expected to continue with a forecast turnover over 75 million € In 2020.

With the launch of its firts european subsidiaries and supported by a growing network of international distributors, the Group expects to achieve 50% of its turnover from exports within the next 3 to 5 years. 10% of sales invested in R&D to gradually reach 15% over the next five years.

See our subsidiaries

More than numbers, results

Horus Pharma growth is measured through concrete results in terms of hiring, product portfolio expansion and performance at the national and international levels.

Employment

With a sustained recruitment policy of 10% annual hiring, Horus Pharma has established itself as a thriving SME and employment generator in the Nice area.

Innovation

Innovation takes the form of a sustained rate of product launches, patent filing and expansion of the product portfolio, which includes more than 50 specialities today, to progressively cover all therapeutic segments in ophthalmology.

International

With an international focus since 2010, Horus Pharma has a voluntary Export policy, through the constant expansion of its distribution network, covering 12 countries in Western Europe, North America and Asia including Russia. This dynamic of extension is coupled with the launch of the first European subsidiaries in 2015.

X 2

In the span of 4 years between 2013 and 2017, the number of Horus Pharma employees has doubled growing to nearly 150 employees today.

> 50

At the rate of 3 to 4 new product launches per year, the laboratory's product portfolio has expanded to bring together some fifty specialties.

97ÈME

The position Horus Pharma holds in the National Ranking for SMEs and most successful independent French ETI

Edition 2014 of the L'Express National Ranking

See our areas of research


Horus Pharma

Products

  • Ophthalmology
    • Corneal edema
    • Ocular dryness
    • Glaucoma
    • DME
    • Allergic conjunctivitis
  • Eye Micronutrition
    • Food supplements
  • Dermatology
    • Eyelids Care and Hygiene
  • Chirurgie

Navigation

  • Cookies policy
  • LEGAL NOTICE
  • About
  • R&D
  • INTERNATIONAL
  • Careers

Contact us

  • Horus Pharma Belux
    Lenniksebaan 451- 1070 Brussels - BELGIUM
  • +32 (0)2 528 05 26
  • info@horus-pharma.be

Follow us

  • Facebook
  • Youtube
  • Pinterest
Agence Web LyonDev

© 2018-2020 - Site réalisé et hébergé par LyonDev - EURL JUML69 - 88 Grande Rue 69340 Francheville - FRANCE